The Jackson Laboratory

The Mouseion at the JAXlibrary
Faculty Research 2021

Faculty Research

1-1-2021

A validated integrated clinical and molecular glioblastoma longterm survival-predictive nomogram.
Sherise D Ferguson
Tiffany R Hodges
Nazanin K Majd
Kristin Alfaro-Munoz
Wajd N Al-Holou

See next page for additional authors

Follow this and additional works at: https://mouseion.jax.org/stfb2021
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Authors
Sherise D Ferguson, Tiffany R Hodges, Nazanin K Majd, Kristin Alfaro-Munoz, Wajd N Al-Holou, Dima Suki,
John F de Groot, Gregory N Fuller, Lee Xue, Miao Li, Carmen Jacobs, Ganesh Rao, Rivka R Colen, Joanne
Xiu, Roel G W Verhaak, David Spetzler, Mustafa Khasraw, Raymond Sawaya, James P Long, and Amy B
Heimberger

Neuro-Oncology Advances
3(1), 1–10, 2021 | doi:10.1093/noajnl/vdaa146 | Advance Access date 31 October 2020

A validated integrated clinical and molecular
glioblastoma long-term survival-predictive nomogram
  

Sherise D. Ferguson†, Tiffany R. Hodges†, Nazanin K. Majd, Kristin Alfaro-Munoz, Wajd N. Al-Holou,
Dima Suki, John F. de Groot, Gregory N. Fuller, Lee Xue, Miao Li, Carmen Jacobs, Ganesh Rao,
Rivka R. Colen, Joanne Xiu, Roel Verhaak , David Spetzler, Mustafa Khasraw , Raymond Sawaya,
James P. Long†, and Amy B. Heimberger†
Departments of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.D.F.,
D.S., L.X., M.L, C.J., R.S., A.B.H.); Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA (G.R.);
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (N.K.M.,
K.A-M. J.F.deG.); Departments of Anatomic Pathology and Neuroradiology, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA (G.N.F.); Department of Biostatistics, The University of Texas MD Anderson Cancer
Center, Houston, Texas, USA (J.P.L.); Hillman Cancer Center, Department of Radiology, University of Pittsburg,
Pittsburg, Pennsylvania, USA (R.C.); Department of Neurosurgery, Seidman Cancer Center & University Hospitals—
Cleveland Medical Center, Cleveland, Ohio, USA (T.R.H.); Department of Neurosurgery, University of Michigan Medical
School, Ann Arbor, Michigan, USA (W.N.A-H.); Caris Life Sciences, Irving, Texas, USA (J.X., Da.S.); Tisch Brain Tumor,
Department of Neurosurgery Duke University Medical Center, Durham, North Carolina, USA (M.K.); The Jackson
Laboratory for Genomic Medicine, Farmington, Connecticut, USA (R.V.)
†Co-lead

primary and senior authors.

Corresponding Authors: For the patient dataset: Amy B. Heimberger, MD, Department of Neurosurgery, Unit 422, The University
of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA (aheimber@mdanderson.org); For the
nomogram application and code: James P. Long, PhD, Department of Biostatistics, Unit 1411, The University of Texas MD Anderson
Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA (JPLong@mdanderson.org).

Abstract
Background. Glioblastoma (GBM) is the most common primary malignant brain tumor in adulthood. Despite
multimodality treatments, including maximal safe resection followed by irradiation and chemotherapy, the median
overall survival times range from 14 to 16 months. However, a small subset of GBM patients live beyond 5 years
and are thus considered long-term survivors.
Methods. A retrospective analysis of the clinical, radiographic, and molecular features of patients with newly
diagnosed primary GBM who underwent treatment at The University of Texas MD Anderson Cancer Center was
conducted. Eighty patients had sufficient quantity and quality of tissue available for next-generation sequencing
and immunohistochemical analysis. Factors associated with survival time were identified using proportional odds
ordinal regression. We constructed a survival-predictive nomogram using a forward stepwise model that we subsequently validated using The Cancer Genome Atlas.
Results. Univariate analysis revealed 3 pivotal genetic alterations associated with GBM survival: both high tumor
mutational burden (P = .0055) and PTEN mutations (P = .0235) negatively impacted survival, whereas IDH1 mutations positively impacted survival (P < .0001). Clinical factors significantly associated with GBM survival included
age (P < .0001), preoperative Karnofsky Performance Scale score (P = .0001), sex (P = .0164), and clinical trial participation (P < .0001). Higher preoperative T1-enhancing volume (P = .0497) was associated with shorter survival.
The ratio of TI-enhancing to nonenhancing disease (T1/T2 ratio) also significantly impacted survival (P = .0022).
Conclusions. Our newly devised long-term survival-predictive nomogram based on clinical and genomic data
can be used to advise patients regarding their potential outcomes and account for confounding factors in
nonrandomized clinical trials.
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Key Points
• Our new long-term survival-predictive nomogram can advise GBM patients on
outcomes.
• The nomogram may help account for factors confounding nonrandomized clinical
trials.

Importance of the Study
Glioblastoma (GBM) survival is approximately a
year. A small subset of GBM patients is afforded
long-term survival but the features that predict
this outcome are not fully delineated. This study
integrates clinical, radiographic, and genomic
data to assess the probability of long-term survival. We performed extensive molecular profiling on a cohort of patients with de novo GBM
and integrated this data with clinical and radiographic features. We then constructed an integrated predictive outcome nomogram based on

The current standard-of-care for treatment of glioblastoma
(GBM) is maximal safe resection followed by concurrent
chemoradiation and cyclic administration of temozolomide.
Despite aggressive, multimodality therapy, the median survival times range from 14 to 16 months.1,2 However, a small
percentage of GBM patients (<3%) live well beyond 5 years,
suggesting that these long-term survivors have a disease
course that is inherently different from that in most GBM patients.3 The factors that define this subset of GBM patients
who defy the odds remain largely unknown. Several small
series have focused on clinical predictors of outcome,4,5
whereas others have focused on molecular determinants of
survival.6–8 Currently available calculators of predictive outcomes in GBM patients are mostly reliant on clinical features
(https://www.eortc.be/tools/gbmcalculator/;
http://cancer4.
case.edu/rCalculator/rCalculator.html). An integrated clinical
and molecular framework for long-term survival (LTS) has yet
to be devised. To that end, the objective of the present study
was to perform an in-depth analysis of a cohort of GBM patients to determine not only the clinical factors but also the
molecular determinants of survival. As a result, we developed
a survival-predictive nomogram to identify confounders that
may be relevant for the assessment of nonrandomized GBM
clinical trials and to enable oncologists to more appropriately
advise patients regarding their potential outcomes.

Methods
Study Population
This study was conducted under The University of Texas
MD Anderson Cancer Center Institutional Review Boardapproved protocol PA15-0636 and consisted of 80 patients
with newly diagnosed GBM who underwent treatment at

age, Karnofsky Performance Scale score, and the
mutational status of IDH1, PTEN, and TP53 which
was validated with The Cancer Genome Atlas.
This long-term survival-predictive score can provide clinicians with a framework to inform patients about their relative chances of long-term
survival. The nomogram will also be a valuable
assessment tool for clinical trial investigators,
regulatory agencies, and other stakeholders to
identify confounding variables influencing the
interpretation of outcomes data.

MD Anderson from November 1, 1996 to December 31, 2015
and had sufficient quality and quantity of tissue available
for next-generation sequencing and immunohistochemical
analysis along with full radiographic and clinical annotation. This study strictly excluded secondary IDH-mutant
GBM with a multi-year prior history of known low-grade
astrocytoma and was focused on de novo, classic spontaneously arising GBM. Patients were stratified into 3
analysis groups: short-term survival (STS; <6 months
[n = 37]), median survival (MTS; ~15 months [n = 22]),
and LTS (>5 years [n = 21]). Four of the patients in the STS
group and 3 of those in the MTS group were censored
because they were lost to follow-up (ie, their exact dates
of death were unavailable). Tumor diagnosis was made
using magnetic resonance (MR) imaging and/or contrastenhanced computed tomography. All of the patients’ initial craniotomies for tumor resection were performed at
MD Anderson. Histological diagnosis in each case was
based on the World Health Organization Classification
and determined by a board-certified pathologist. The patients’ demographic, clinical, and radiographic data were
reviewed. Clinical variables included age at surgery, sex,
and Karnofsky Performance Scale (KPS) score. Volumetric
analysis was performed on immediate preoperative MR
imaging. Preoperative and postoperative tumor volumes
measured using MR imaging were quantified prospectively using Vitrea (version 2) or MedVision (version 1.41)
software. These software programs allow for calculation of
the tumor area as outlined on selected axial or coronal images followed by estimation of the tumor volume based on
the known thickness of the slice. Tumor contrast-enhanced
volume was defined as the area of increased signal intensity on contrast-enhancing T1-weighted MR images.
Extent of resection (EOR) was calculated based on the preoperative and postoperative tumor volumes. A subset of
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Immunohistochemical Analysis
Immunohistochemical analysis was performed using entire sections of formalin-fixed, paraffin-embedded GBM
samples with automated staining techniques as we described previously.9 Dilutions and conditions were performed according to package insert instructions; they
were optimized and validated and met the standards and
requirements of the Clinical Laboratory Improvement
Amendments, College of American Pathologists,
and International Organization for Standardization.
Immunohistochemistry results were evaluated independently by 6 board-certified neuropathologists. The primary
anti-programmed death-ligand 1 (PD-L1) antibody SP142
(Spring Bioscience) was used for detection. The chromogenic reporter 3, 3′-diaminobenzidine was used to facilitate colorimetric visualization of the antibody, yielding a
brown stain that could be analyzed under a light microscope. For an SP142 clone, the Rabbit LINKER visualization system (Dako) was used. The staining was regarded
as positive if its intensity on the membranes of tumor
cells was greater than 1+ on a semiquantitative scale of
0–3+ (0 for no staining, 1+ for weak cytoplasmic staining,
2+ for moderate membranous staining, and 3+ for strong
membranous staining) and the percentage of positively
stained cells was greater than 5%. During the validation
process for each analysis using immunohistochemistry,
any interpathologist variability in evaluation was addressed in a microscopic examination session by all 6
pathologists led by the medical director.

Next-Generation Sequencing Methods
Next-generation sequencing was performed with genomic DNA isolated from formalin-fixed, paraffinembedded tumor samples on the Illumina NextSeq
platform. A custom-designed SureSelect XT assay
(Agilent Technologies) was used to enrich 592 wholegene targets (http://www.carislifesciences.com). Genetic
variants were detected with greater than 99% confidence
interval based on allele frequency and amplicon coverage, with an average sequencing depth of coverage
greater than 500× and analytic sensitivity of 5% variant frequency. Variants were classified according to the
American College of Medical Genetics and Genomics
guidelines.10 Pathogenic variants, defined as known
pathogenic mutations that promote tumorigenesis,
presumed pathogenic variants (not germline with evidence of pathogenicity in functional assays), or variants
that were not wild type but could be associated with
protein changes, were selected for analysis of their association with survival. Wild type and benign variants
that occur during somatic development and are not capable of causing disease were not included. Tumor mutational burden (TMB) was calculated by counting all
nonsynonymous missense mutations not previously
reported as germline alterations. Specifically, TMB was

calculated using somatic nonsynonymous missense
mutations in accordance with the TMB Harmonization
Project (Friends of Cancer Research; http://www.focr.
org/tmb), adding nonsynonymous, nonsense, in-frame
indel, and frameshift variants after filtering out presumed germline variants determined from the Genome
Aggregation Database (release 2.1; https://gnomad.
broadinstitute.org/), the Database of Single Nucleotide
Polymorphisms (human build 151; https://www.ncbi.
nlm.nih.gov/snp/), and the Caris Life Sciences in-house
benign database. About 1.4 Mb per tumor sample was
sequenced.11

Statistical Methods
Univariate analysis to assess the associations of individual
features with STS, MTS, and LTS was performed using an
ordinal proportional odds regression model. Confidence
intervals (CIs) were computed using Wald statistics and
P values were determined using likelihood ratio tests.
Features with P values of up to .10 in the univariate analysis were subjected to multivariate analysis. To select the
best features for the model, the forward stepwise selection was used with the Akaike information criterion (AIC).
AIC balances how well a model explains the data (quality
of predictions) with the model’s complexity (number of
features). The goal is to have a model that explains data
well but is not too complex. Lower AIC values are better.
Forward stepwise selection starts by constructing p
single-feature models in which p is the number of features under consideration. The best-fitting single-feature
model, as measured by AIC, is chosen for step 2. In step 2,
p−1 two-feature models are built. Each model uses the
single best feature from the first step of the algorithm and
one of the remaining p−1 features. The 2 features used in
the best model are then selected for step 3. This process
continues until all features are used or the AIC begins to
increase (suggesting an excessively complex model). The
results of the forward stepwise selection are shown in
Supplementary Figure 1.
To address the differing prevalence of STS, MTS, and LTS
in the MD Anderson cohort and GBM patient data in The
Cancer Genome Atlas (TCGA), Bayes’ theorem was used.
Let πm and πt be the known class prevalence for the MD
Anderson and TCGA patients, respectively. Also, let f (x|c)
be the probability of observing features x given class c ,
where class c is STS , MTS , or LTS . Then the model outputs
f (x|c)πm (c)
.
πm (c|x) = 
c f (x|c)πm (c)

For making predictions on theTCGA cohort the probabilities
f (x|c)πt (c)
πt (c|x) = 
c f (x|c)πt (c)

were performed. Our strategy was to use the known
πm (c|x) and πm (c) to determine f (x|c) from using the first
equation. f (x|c) was then put into the second equation
(along with πt (c), which is known) to determine πt (c|x). Of
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patients had initial diagnostic biopsies at outside institutions followed by definitive resection at MD Anderson. All
“second-look” surgeries were performed within 6 weeks of
biopsy confirming the tumor to be GBM.
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note, f (x|c) can only be determined up to a multiplicative
constant.
At
fixed
we
seek
sought
the
vector
x,
f = f (x|c) = ( f (x|STS), f (x|MTS), f (x|LTS)),
which
minimizes

g( f ) =

ã2
Å
f (x|c ∗ )πm (c ∗ )
.
πm (c ∗ |x) − 
c f (x|c)πm (c)
c∗

We found f at each vector of probabilities in the grid using
a Newton-type algorithm.
Statistical analyses were performed using R statistical
software (version 3.5.1) with packages survival v3.1–8,
MASS 7.3–51.1, and plotted using gplot v2_3.2.1.

Results
Characteristics of the Patient Cohort
The median age of the MD Anderson GBM patient cohort
was 57 years (range, 25–81 years), their median preoperative KPS score was 90 (range, 40–100), and 63% (n = 50)
of them were male (Table 1). Preoperative imaging revealed that tumor necrosis predominated in the analyzed cohort, which is consistent with the radiographic
features of GBM. We performed volumetric analysis on
the T1 contrast-enhancing portion of the tumor, its T2/
fluid-attenuated inversion recovery (FLAIR) volume and
its MRI tumor necrosis characteristics. No volumetric
data were available for one patient. The median preoperative T1 contrast-enhancing disease volume was 32.1 cm3
  
Table 1.

Clinical Characteristics of the GBM Patient Cohort (N = 80)

Characteristic

n

%

Female

30

38

Male

50

62

No

54

68

Yes

25

31

1

1

Sex

Clinical trial enrollment

Unknown
No

22

29

Yes

55

71

77

96

3

4

GTR

57

74

STR

20

26

Surgical approach
Biopsy
EOR (n = 77)

EOR, extent of resection; GTR, gross total resection; STR, subtotal
resection.

  

Clinical Factors Associated With Survival of GBM
Patients
The median overall survival time in the cohort was 1.2 years,
with 37 (46%) experiencing STS, 22 (28%) experiencing MTS,
and 21 (26%) experiencing LTS. Consistent with reports in the
literature,5,6 univariate analysis demonstrated that age was a
significant predictor of overall survival (P < .0001; odds ratio
[OR], 0.88 [95% CI, 0.84–0.92]; Table 2). Overall survival durations were shorter in male than in female patients (P = .0164;
OR, 0.34 [95% CI, 0.14–0.85]). Additionally, patients with
higher preoperative KPS scores had longer survival than
did patients with lower scores (P < .0001; OR, 1.09 [95% CI,
1.04–1.14]). Clinical trial enrollment at any point in the patients’ treatment course impacted the outcome, with trial participants having a longer survival (P < .0001; OR, 6.52 [95% CI,
2.51–16.92]). Multivariant analysis showed that higher KPS
was significantly associated with clinical trial participation
(P = .0143). Clinical trial participation was not significantly associated with IDH1 status (P = .3271).

The T1/T2 Ratio Impacts GBM Patient Survival

Tumor necrosis (n = 77)

Craniotomy/resection

(range, 0.4–111.0 cm3), and the median T2/FLAIR volume
was 79.5 cm3 (range, 4.9–300.8 cm3). Five tumors did not
show sufficient enhancement on T1-weighted sequences to
be volumetrically measured, and 4 had no measurable T2
volumes. For all other patients (n = 71), we calculated the
ratio of contrast-enhancing to nonenhancing disease (T1/
T2 ratio), finding a median value of 41%. Tumor necrosis
was present in 55 cases (69%), with a median volume of
10.6 cm3 (range, 0.2–75.5 cm3). Three patients underwent
biopsy only, with the remaining 77 undergoing resection.
Of these patients, 74% (n = 57) has a gross total resection
(≥97% resection of T1 contrast-enhancing disease), and
66% (n = 51) had 100% resection of T1 contrast-enhancing
disease. Three patients had diagnostic biopsies at outside
institutions and subsequently presented to MD Anderson
and underwent resection; we included these patients in
the survival analysis. The overall median EOR was 100.0%
(range, 50.5–100.0%) for T1 contrast-enhancing disease
and 63.1% (range, 14.4–100.0%) for T2/FLAIR disease.
Postoperatively, T2/FLAIR disease in one patient could not
be assessed due to a large area of postoperative ischemic
change that was indistinguishable from residual T2/FLAIR
disease.

From a radiographic perspective, a higher preoperative T1
contrast-enhancing tumor volume (P = .0497; OR, 0.98 [95%
CI, 0.97–1.00]) was associated with a shorter survival time.
More specifically, the T1/T2 ratio correlated negatively with
survival. Patients with larger T1/T2 ratios (sample patient—
Figure 1) had a significantly shorter survival (P = .0022;
OR, 0.08 [95% CI, 0.01–0.45]). Among the patients who
experienced LTS (n = 21), volumetric data were available
for 17, and of those, 15 (88%) had 100% resection of the
T1-enhancing component of the tumor (median, 100.0%
[range, 57.9–100.0%]). Volumetric data were available for
all short-term survivors (n = 37), with 21 (57%) undergoing
100% resection (24 patients had ≥97% resection).
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Univariate Analysis of the Study Patients (N = 80): Clinical and Radiographic Factors

Feature

n

OR

95% CI

P

Age

—

0.8797417

0.84–0.92

<.0001

Female

30

—

—

Male

50

0.3437707

0.14–0.85

KPS score

—

1.0853484

1.04–1.14

<.0001

T1-enhancing volume

—

0.9839941

0.97–1.00

.0497

T2 volume including T1

—

1.0027202

1.00–1.01

.4802

T1/T2 volumetric ratio

—

0.0807405

0.01–0.45

.0022

Necrosis volume

—

0.9699149

0.93–1.01

.0817

Volumetric EOR based on enhancement

—

1.0087027

0.96–1.06

.7141

Volumetric EOR based on T2/FLAIR disease

—

0.9947252

0.98–1.01

.5930

GTR

57

—

—

.3419

STR

16

0.4584197

0.15–1.40

Biopsy

3

0.5608276

0.04–7.37

Negative

46

—

—

Positive

6

0.7866907

0.13–4.75

TMB

—

0.7378053

0.58–0.94

Clinical trial enrollment

—

Sex
.0164

EOR based on enhancing disease

PD-L1 status

No

54

—

—

Yes

25

6.5197993

2.51–16.92

No

38

—

—

Yes

32

3.9444285

1.52–10.22

.7869
.0055
<.0001

MGMT methylation
.0032

KPS, Karnofsky Performance Scale; EOR, extent of resection; GTR, gross total resection; STR, subtotal resection; TMB, tumor mutational burden.

  
Genetic Determinants of GBM Patient Survival

Construction of the Predictive Nomogram

Univariate analysis revealed that 2 gene mutations were significantly associated with survival (Table 3). IDH1 mutations
had the biggest impact on survival, with patients having
IDH1-mutant tumors (n = 14) surviving longer than did those
having IDH1–wild-type tumors (P < .0001; OR, 97.8 [95% CI,
10.79–886.91]). Most of the long-term survivors (13 of 21) had
this mutation, whereas none of the short-term survivors had it.
PTEN status also influenced survival, with patients having tumors with mutations of the PTEN genes experiencing shorter
survival than did those with PTEN–wild-type tumors (P = .0235;
OR, 0.23 [95% CI, 0.06–0.94]). None of the IDH1-mutated patients (n = 14) had PTEN mutations (n = 11). However, the correlation was not statistically significant. PD-L1 expression was not
associated with survival in our cohort.
Consolidating the overall mutational landscape, we
evaluated the association of TMB with survival and found
that a high TMB negatively impacted survival (P = .0055;
OR, 0.73 [95% CI, 0.58–0.94]). IDH1 mutation was significantly associated with lower TMB (P = .0003). Furthermore,
O[6]-methylguanine-DNA
methyltransferase
(MGMT)
methylation was associated with LTS (P = .0032; OR, 3.94
[95% CI, 1.52–10.22]).

The dataset was missing the following variables for
some patients: PD-L1 expression (n = 28), MGMT methylation status (n = 10), T1/T2 ratio (n = 9), volumetric
EOR of enhancing disease (n = 7), volumetric EOR of T2/
FLAIR disease (n = 7), TMB (n = 6), T1-enhancing volume
(n = 5), EOR of enhancing disease (n = 4), T2 volume including T1 (n = 4), necrosis volume (n = 3), KPS score
(n = 2), and clinical trial participation (n = 1). For PD-L1
tumor staining and TMB analysis, these assays were becoming available as a Clinical Laboratory Improvement
Amendments approved assay during data acquisition.
The remaining missing variables were mostly related to
the inability to precisely measure multifocal and complex images. Genomic variables were coded as unfavorable if they were considered pathogenic or presumed
pathogenic based on the American College of Medical
Genetics and Genomics guidelines.10 We coded all other
genetic alterations, such as benign, variant not detected,
and variant of unknown significance, as neutral. Thus all
genomic variables were binary. We then correlated each
variable with STS, MTS, and LTS and ranked based on
the significance of each correlation. We considered all
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T1 vol.

T2/FLAIR vol.

Figure 1. Representative MR images of a newly diagnosed GBM patient at presentation demonstrating a T1 gadolinium contrast-enhancing
volume of 14.2 cm3 (left) and T2/FLAIR volume of 104.4 cm3 (right). In this patient, the T1/T2 ratio was 0.13.
  

variables with P values less than .1 in the univariate analysis to be potentially interesting.
We found that clinical trial enrollment correlated with
survival. However, we eliminated this feature from the
survival-predictive nomogram because clinical trial participation cannot be determined at the time of GBM diagnosis.
We also removed TMB from our survival-predictive nomogram because its definition varies from assay to assay,
making reproduction with an independent dataset such as
those in the TCGA difficult.

Model Building
We used a proportional odds ordinal logistic regression
model to predict STS, MTS, and LTS probability given according to patient features (covariates).12 We used forward
stepwise selection with the AIC to select the best features
for the model implemented using the MASS package in R
statistical software.13 We used age, IDH1, KPS score, PTEN,
and TP53 mutation status in the final model. The genomic
variables IDH1, PTEN, and TP53 are all binary (either mutated or not mutated). Supplementary Figure 1 shows that
the model assigned low probability of LTS to the patients
who actually experienced STS (concentration of red region
near 0) and high probability of LTS to patients who actually
experienced LTS (blue region mode near 1). The code used
for building the model can be found at https://github.com/
longjp/GBMpredict. Statistical details of the proportional
odds model, AIC, and forward stepwise selection are described above.

Evaluation and Validation of the SurvivalPredictive Nomogram
We externally validated the model using GBM patient
data from TCGA (n = 592) with the following patient/survival proportions: STS (0–1 year), 0.42; MTS (1–5 years),
0.52; and LTS (5+ years), 0.06. These proportions differed
markedly from the proportions in our cohort, in which patients with LTS were deliberately oversampled to obtain
enough patients to build a robust model (STS, 0.46; MTS,
0.28; LTS, 0.26). To account for these differences in survival
prevalence, we adjusted our probabilistic predictions to
reflect the prevalence in TCGA using Bayes’ theorem as
described above.
We then applied the model to the TCGA cohort and made
probabilistic predictions for each patient. For any given
value of age, KPS score, IDH1, PTEN, and TP53 mutation
status, we obtained a set of 3 probabilities corresponding
to the likelihood of STS, MTS, and LTS. Since 95 patients in
the TCGA cohort are censored (patients are STS or MTS but
alive at the time of the last follow-up so true survival is at
least STS or MTS), we use the concordance index to assess
the quality of these predictions.12 The C-index is the proportion of comparable pairs of samples where the model
predictions agree with the actual outcomes. A C-index of
0.5 corresponds to a useless model (random guessing)
and 1.0 to a perfect model. Our model achieves a C-index
of 0.66 on the independent TCGA cohort (P < .00001). The
finalized embargoed nomogram can be found at https://biostatistics.mdanderson.org/shinyapps/GBM_Predict/ (username: GBM; password: predict; Figure 2).
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Univariate Analysis of the Study Patients (N = 80): Molecular Variables

Variable {“Gene?”}

Mutationa

n

OR

95% CI

APC

0

79

—

—

1

1

—

—

0

78

—

—

1

2

1.5837893

0.19–13.36

CDKN2A

0

79

—

—

1

1

—

—

EGFR

0

67

—

—

1

13

0.5516976

0.16–1.86

0

79

—

—

1

1

—

—

FGFR3

0

79

—

—

1

1

—

—

IDH1

0

66

—

—

1

14

97.8096211

10.79–886.91

KRAS

0

79

—

—

1

1

—

—

0

78

—

—

1

2

0.5930654

0.05–7.64

NF1

0

75

—

—

1

5

0.4264895

0.07–2.50

PIK3CA

0

73

1

7

0
1

BRAF

FBXW7

MUTYH

—

—

1.6332647

0.41–6.59

69

—

—

11

0.2313771

0.06–0.94

0

79

—

—

1

1

—

—

SUFU

0

79

—

—

1

1

—

—

TP53

0

57

—

—

1

23

2.4522865

0.93–6.45

PTEN
PTPN11

a0,

P

.6671

.3197

<.0001
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no mutation; 1, mutation.

  
Discussion
Long-term survival in patients with GBM is uncommon,
and survival for at least 5 years is quite rare. In this report, we describe clinical, radiographic, and molecular
features associated with LTS in this patient population.
These key features should be accounted for during clinical trial interpretation as confounders when assessing
outcomes in GBM patients. Notably, 50% of the long-term
survivors in our study participated in at least one clinical
trial. This may explain why the initial results of many uncontrolled single-institution GBM studies appear to be
promising but the effect is diminished once the studies
are expanded to multi-institutional controlled trials.
Researchers have shown that clinical features such as
young age and a good KPS score at the time of diagnosis
are favorable prognostic factors in GBM patients.14–16

Because long-term survivors represent only a small subset
of GBM patients, their clinical characteristics were only
minimally addressed in earlier studies, often with limited
sample sizes and follow-up durations.17–21 In one study,
investigators evaluated 55 patients with GBM who underwent surgery and adjuvant radiotherapy and survived beyond 36 months.6 That study demonstrated that LTS was
associated with high functional status and young age.
Another retrospective analysis compared 16 long-term
survivors who survived for more than 2 years with shortand medium-term survivors and found that KPS score at
diagnosis, age, initial tumor resection (as opposed to biopsy), chemoradiation, and early progression were factors
associated with survival in these groups.17 However, few
studies22 account for radiographic, clinical, and molecular determinants of the outcome as in the present study.
Although researchers have attempted to correlate features
of advanced imaging modalities such as radiomic and
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Patient score
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Figure 2. The application for GBM survival prediction using the survival-predictive nomogram. A representative clinical example is shown in
which a 43-year-old GBM patient with a KPS score of 70 had an IDH1-mutant tumor. This patient had a 2%, 72%, and 26% chance of being a shortterm survivor (<6 months), long-term survivor (>5 years), and median-term survivor (~15 months), respectively. Two percent of patients had this
outcome.
  

textural MR imaging features with GBM outcome,23–25 the
present study shows the utility of conventional standard
MR imaging in assessing the outcome of GBM. An advantage of the nomogram is the ease of interrogation of
outcome in the clinical domain relative to more complex
mathematical modeling even if the latter is more accurate.26 Furthermore, our analysis demonstrated that the
influence of a pathogenic mutation of IDH1, which is directly associated with age, surpassed that of many other
previously documented factors. One could argue that the
presence of an IDH1 mutation may demonstrate that these
cases are not classical GBM. There is a growing consensus
that IDH-mutant astrocytomas and IDH-wildtype, grade 4
diffuse astrocytomas are 2 biologically distinct tumors.27,28
Notably, board-certified neuropathologists who advise regarding the World Health Organization criterion reviewed
all of the cases, none of the analyzed cases were secondary GBM, and IDH1 mutations were present in about
5% of cases in a previous study.29
Because the median EOR in our study cohort was
100%, an excellent resection is a baseline criterion for
subsequent application of the survival-predictive nomogram. In a recently published GBM nomogram, in addition to age, KPS, and gender, unlike the current study,
these authors included EOR to their internally validated
nomogram.30 Gorlia et al.31 published a large study
compiling data from 573 GBM patients to construct a
predictive nomogram for 2-year survival with a focus
on the impact of MGMT status. However, at that time no
validation set was available and our current study has
a greater depth of molecular profiling. Genetic analysis
provided the compelling perspective that the presence
of a pathogenic IDH1 mutation is one of the strongest
influences on LTS in GBM patients. To account for the

possibility of inclusion of patients with secondary GBM
in our LTS cohort, we performed genetic analysis of the
long-term survivors that demonstrated all of their tumors had intact ATRX and that none of them had previously documented gliomas, indicating that these were
de novo GBMs. None of the IDH-mutant tumors showed
the classic molecular alteration triad of IDH mutation,
TP53 mutation, and ATRX mutation, which represents
a rare subtype. Among prior profiling of IDH mutants
that are non-co-deleted, approximately 95% are TP53
and 75% are ATRX mutant.32,33 We validated the GBM
survival-predictive nomogram using GBM patient data
in TCGA because validation in other large cases series
was not possible, as outcome data were only reported
for up to 3 years, the numbers of 5-year survivors
lacked sufficient statistical power, and/or genomic data
were insufficient.5,34–37 In the future, more molecular
information on patient GBMs will be available both
because it is a requirement for diagnosis using World
Health Organization criteria and because genetic profiling is becoming more mainstream. Therefore, we will
update the nomogram in the future to enhance its accuracy in survival prediction.
There are some study limitations that warrant discussion. The nomogram was developed based on the data
from an academic institution, and although validated with
TCGA, may not be reflective of patients treated in a general
community practice setting. Biases such as the overall surgical EOR from the academic group was notably high and
may not be recapitulated without neuro-oncology neurosurgical expertise. Despite the extensive tumor profiling
performed, the patient cohort itself is not large relative
to more common cancers. Additionally, epigenetic profiling would further enhance the predictive value of the
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